Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma

Annals of Oncology

Volumn 20, Issue 7, 2009, Pages 1275-1279

  Nutting, Chris M ^a   Van Herpen, C M L ^b   Miah, A B ^a   Bhide, S A ^a   Machiels, J P ^c   Buter, J ^d   Kelly, C ^e   De Raucourt, D ^f   Harrington, K J ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^f CENTRE FRANÇOIS BACLESSE   (France)

Author keywords

3 AP Triapine; Chemotherapy; Head and neck cancer

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; DOCETAXEL; FLUOROURACIL; METHOTREXATE; PLATINUM COMPLEX;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG TOLERABILITY; FATIGUE; HEAD AND NECK CARCINOMA; HUMAN; METASTASIS POTENTIAL; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME;

EID: 67650394382     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn775     Document Type: Article

References (23)

1. Liggett W, Forastiere AA. Chemotherapy advances in head and neck oncology. Semin Surg Oncol 1995; 11: 265-271.
2. Al-Sarraf M. Chemotherapy strategies in squamous cell carcinoma of the head and neck. Crit Rev Oncol Hematol 1984; 1: 323-355.
3. Forastiere AA, Metch B, Schuller DE et al. Randomised comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck: A Southwest Oncology Group study. J Clin Oncol 1992; 10: 1245-1251.
4. Clark JI, Hofmeister C, Choudhury A et al. Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma. Cancer 2001; 92: 2334-2340.
5. Jacobs C, Lyman G, Velez-Garcia E et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992; 10: 257-263.
6. Kirby AM, A'Hern RP, D'Ambrosio C et al. Gefitinib (ZD1839, Iressa™) as palliative treatment in recurrent or metastatic head and neck cancer. Br J Cancer 2006; 94: 631-636.
7. Vermorken JB, Trigo J, Hitt R et al. Open-label, uncontrolled, multicentre phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous-cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25(16): 2171-2177.
8. Amrein PC, Weitzman SA. Treatment of squamous cell carcinoma of the head and neck with cisplatin and 5-fluorouracil. J Clin Oncol 1985; 3: 1632-1639.
9. Kish JA, Weaver A, Jacobs J et al. Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer 1984; 53: 1819-1824.
10. Basaran M, Bavbek SE, Gullu I et al. A phase II study of paclitaxel and cisplatin combination chemotherapy in recurrent or metastatic head and neck cancer. J Chemother 2002; 14: 207-213.
11. Vermorken JB, Mesia R, Rivera F et al. Platinum based chemotherapy plus Cetuximab in head and neck cancer. N Engl J Med 2008; 359(11): 1116-1127.
12. Finch RA, Liu M, Grill SP et al. Triapine® (3-aminopyridine-2-carboaldehyde thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumour activity. Biochem Pharmacol 2000; 59: 983-991.
13. Murren J, Modiano M, Clairmont C et al. Phase I and pharmacokinetic study of Triapine®, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumours. Clin Cancer Res 2003; 9: 4092-4100.
14. Wadler S, Makover D, Clairmont C et al. Phase I and pharmacokinetic study of the ribonucleotide reductase, 3-aminopyridine-2-carboaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion. J Clin Oncol 2004; 22: 1553-1563.
15. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 2000; 92: 205-216.
16. Glick JH, Zehngebot LM, Taylor SG 4th. Chemotherapy for squamous cell cancer of the head and neck: A progress report. Am J Otolaryngol 1980; 1: 306-323.
17. Catimel G, Vermorken JB, Clavel M et al. A phase II study of gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck: EORTC Early Clinical Trials Group. Ann Oncol 1994; 5: 543-547.
18. Ma B, Goh BC, Tan EH et al. A multicentre phase II of 3-aminopyridine2- carboaldehyde thiosemicarbazone (3-AP, Triapine®) and gemcitabine in advanced non-small cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells. Invest New Drugs 2008; 26(2): 169-173.
19. Karp JE, Giles FJ, Gojo I et al. A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboaldehyde thiosemicarbazone (3-AP, Triapine®) in combination with the nucleoside analogue fludarabine for patients with refractory acute leukaemias and aggressive myeloproliferative disorders. Leuk Res 2008; 32(1): 71-77.
20. Giles FJ, Fracasso PM, Kantarjian HM et al. Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukaemia. Leuk Res 2003; 27: 1077-1083.
21. Chun HG, Leyland-Jones B, Cheson BD. Fludarabine phosphate: A synthetic purine antimetabolite with significant activity against lymphoid malignancies. J Clin Oncol 1991; 9: 175-188.
22. Symonds RP, Collingwood M, Kirwan J et al. Concomitant hydroxyurea plus radiotherapy versus radiotherapy for carcinoma of the uterine cervix: A systematic review. Cancer Treat Rev 2004; 30: 405-414.
23. Barker CA, Burgan WE, Carter DJ et al. In vitro and in vivo radiosensitization induced by the ribonucleotide reductase inhibitor Triapine (3-aminopyridine2-carboxaldehyde-thiosemicarbazone). Clin Cancer Res 2006; 12(9): 2912-2918.